Medivate Partners

Cipherome is a biotech company focused on delivering personalized drug treatments tailored to individuals' unique genetic profiles. The company operates on the principle that every person deserves optimal medical care, recognizing that variations in drug reactions can result from inherited genetic factors. Its innovative platform integrates artificial intelligence and bioinformatics to analyze genomic information, allowing for the identification of the most effective medications for each patient. By providing healthcare professionals with insights into personalized drug reaction risks, Cipherome aims to minimize the occurrence of serious side effects and adverse drug reactions, ensuring safer and more effective treatment options across diverse patient populations.

SoVarGen is a biotechnology company focused on developing innovative therapeutics for patients with neurological diseases, particularly those related to intractable central nervous system disorders resulting from low-level somatic mutations. The company employs unique research and development strategies that aim to address the shortcomings of current treatments for brain diseases. By offering differentiated methods and resources, SoVarGen seeks to create a new approach to treatment development, ultimately enabling patients to access effective therapies more quickly.

Artiva Biotherapeutics is a biotech company focused on developing and manufacturing cellular immunotherapies for cancer patients. Founded in 2019 and based in San Diego, California, Artiva specializes in off-the-shelf, allogeneic natural killer (NK) cell therapies aimed at treating various hematologic cancers and solid tumors. The company's product pipeline targets specific antigens, including CD20 and CD19 for B-cell lymphomas, as well as HER2 for certain solid tumors. Artiva's approach emphasizes the therapeutic potential of NK cells and aims to overcome challenges in scaling and manufacturing these therapies. The company is committed to delivering safe, effective, and readily accessible cell therapies to benefit cancer patients. Artiva operates as a subsidiary of Green Cross Holdings Corporation.

Cognate BioServices, Inc. is a contract bioservices organization based in Memphis, Tennessee, specializing in the development and manufacturing of cell and cell-mediated gene therapy products for biotechnology companies and institutions across the United States. Established in 2002 and formerly known as Cognate Therapeutics, the company offers a comprehensive range of services, including process development, regulatory compliance, assay development, preclinical support, stem cell services, cell banking, and characterization. Cognate is known for its expertise in both adherent and non-adherent cell systems, as well as advanced cryopreservation techniques. With a team of highly experienced professionals and cGMP facilities, Cognate BioServices is positioned as a leading contract manufacturer in the field of cell-based products, bolstered by a strategic partnership with Akron Biotechnology, LLC.

WindMIL Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Princeton, New Jersey. It focuses on developing innovative cell therapies for cancer patients by translating insights from bone marrow immunology. The company specializes in a novel class of therapies known as Marrow Infiltrating Lymphocytes (MILs), which are derived from memory T cells found in the bone marrow. By reactivating dormant T-cells and utilizing bone marrow-derived lymphocytes, WindMIL Therapeutics aims to create effective immunotherapies that harness the unique properties of the bone marrow, ultimately improving treatment options for oncology patients.

Cognate BioServices, Inc. is a contract bioservices organization based in Memphis, Tennessee, specializing in the development and manufacturing of cell and cell-mediated gene therapy products for biotechnology companies and institutions across the United States. Established in 2002 and formerly known as Cognate Therapeutics, the company offers a comprehensive range of services, including process development, regulatory compliance, assay development, preclinical support, stem cell services, cell banking, and characterization. Cognate is known for its expertise in both adherent and non-adherent cell systems, as well as advanced cryopreservation techniques. With a team of highly experienced professionals and cGMP facilities, Cognate BioServices is positioned as a leading contract manufacturer in the field of cell-based products, bolstered by a strategic partnership with Akron Biotechnology, LLC.

Genopis specializes in plasmid DNA based technology and provides contract development and manufacturing organization (CDMO) opportunities to help your company reach its clinical and commercial goals.

SillaJen, Inc. is a biotechnology company based in Busan, South Korea, with additional offices in Seoul and San Francisco. Established in 2006, SillaJen specializes in the development and commercialization of oncolytic immunotherapy products, leveraging its proprietary SOLVE™ platform. The company's lead product, Pexa-Vec, is currently undergoing Phase III clinical trials for the treatment of advanced liver cancer. In addition to Pexa-Vec, SillaJen is advancing other therapies, including JX-929, which targets breast, colorectal, and pancreatic cancers, and JX-970, aimed at specific tumor tissues. The company also has a series of modified vaccinia vaccines under the JX-900 designation. SillaJen has entered into cooperative research agreements with the National Cancer Institute to explore combination therapies for colorectal cancer. Through these efforts, SillaJen aims to enhance treatment options for various cancers, utilizing innovative oncolytic approaches.

WCCT Global is a provider of outsourced early drug development services tailored for the pharmaceutical, biotechnology, and medical device sectors. The company specializes in clinical study services, offering comprehensive support that includes regulatory guidance, program management, patient recruitment, and data management. Additionally, WCCT Global focuses on strategic consulting, particularly for special disease populations, pediatric groups, and areas such as ethno-bridging and cardiac safety. By acting as a development partner, the company aims to enhance the efficiency and effectiveness of clinical trials.